Giulia Fiorentini

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: July 23, 2026

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: March 18, 2026

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Journal: The journal of headache and pain

Published: December 20, 2025

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Journal: The journal of headache and pain

Published: December 20, 2025

Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study.

Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study.

Journal: Journal of neurology

Published: August 20, 2025

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Journal: The journal of headache and pain

Published: July 28, 2025

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.

Journal: The journal of headache and pain

Published: April 20, 2025

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).

Journal: Journal of neurology

Published: March 15, 2025

Italian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancy.

Italian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancy.

Journal: Journal of endocrinological investigation

Published: February 16, 2025

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.

Journal: Journal of neurology

Published: December 08, 2024

Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.

Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.

Journal: Brain sciences

Published: August 30, 2024

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Journal: Neurology and therapy

Published: August 06, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026